Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial - Jones, Jeffrey A; Robak, Tadeusz; Brown, Jennifer R; Awan, Farrukh T; Badoux, Xavier; Coutre, Steven; Loscertales, Javier; Taylor, Kerry; Vandenberghe, Elisabeth; Wach, Malgorzata; Wagner-Johnston, Nina; Ysebaert, Loic; et al. (The Lancet. Haematology, 2017)
Keywords: Aged; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal - therapeutic use; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Male; Middle Aged; Neutropenia - chemically induced; Protein Kinase Inhibitors - therapeutic use; Purines - adverse effects; Purines - therapeutic use; Quinazolinones - adverse effects; Quinazolinones - therapeutic use; Treatment Outcome